CSMD1 and gastric cancer: Another GC study confirmed the association between CSMD1 mutation with TMB and high PDL1 expression and increased survival supporting the potential of CSMD1 as a biomarker for assessing immune checkpoint inhibitor therapy in GC patients [74].